Medrol®(methylprednisolone)

Medrol (methylprednisolone) is indicated for a wide range of conditions including: endocrine disorders (adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia from cancer); rheumatic disorders (rheumatoid arthritis, ankylosing spondylitis, bursitis, gouty arthritis, psoriatic arthritis); collagen diseases (lupus, dermatomyositis, acute rheumatic carditis); dermatologic diseases (pemphigus, severe psoriasis, Stevens-Johnson syndrome); allergic conditions (severe asthma, allergic rhinitis, drug hypersensitivity reactions); ophthalmic diseases (uveitis, keratitis, allergic conjunctivitis); respiratory diseases (symptomatic sarcoidosis, berylliosis); hematologic disorders (acquired hemolytic anemia, thrombocytopenic purpura); neoplastic diseases (leukemias and lymphomas); gastrointestinal diseases (ulcerative colitis, regional enteritis); and neurological conditions (multiple sclerosis exacerbations).

Medrol is contraindicated in patients with systemic fungal infections and in patients with known hypersensitivity to methylprednisolone or any component of the formulation. Live or live attenuated vaccines are contraindicated during immunosuppressive corticosteroid dosing.

Key warnings include: increased susceptibility to infections (viral, bacterial, fungal) due to immunosuppression; potential reactivation of latent tuberculosis (monitor during prolonged therapy); serious or fatal varicella and measles infections in non-immune patients; hepatitis B reactivation (screen before treatment); ophthalmic effects including cataracts and glaucoma with prolonged use; electrolyte disturbances (hypertension, hypokalemia, fluid retention); psychological effects (mood changes, insomnia, depression, psychosis); adrenal suppression requiring gradual dose tapering after prolonged therapy (abrupt discontinuation is dangerous).

Common adverse reactions include: fluid and electrolyte disturbances (sodium retention, hypertension, potassium loss); musculoskeletal effects (muscle weakness, osteoporosis, tendon rupture, aseptic necrosis of bone); gastrointestinal effects (peptic ulcers, pancreatitis, esophagitis); dermatologic effects (impaired wound healing, thin fragile skin, bruising); endocrine effects (Cushingoid appearance, growth suppression in children, menstrual irregularities); ophthalmic effects (cataracts, glaucoma, increased intraocular pressure); neurological/psychiatric effects (increased intracranial pressure, convulsions, headache, mood changes, insomnia).

Medrol (methylprednisolone) is a synthetic glucocorticoid (corticosteroid) available as oral tablets in strengths of 2 mg, 4 mg, 8 mg, 16 mg, and 32 mg. Methylprednisolone is a white to practically white, odorless, crystalline powder that is readily absorbed from the gastrointestinal tract. It exerts anti-inflammatory and immunosuppressive effects.